^○Junya FUJINO^{1, 2}, Shisei TEI^{1, 2, 3, 4}, Ryosaku KAWADA², Kathryn F. JANKOWSKI⁵, Toshiya MURAI², Hidehiko TAKAHASHI^{1, 2, 6} (1. Medical Institute of Developmental Disabilities Research, Showa University, 2. Department of Psychiatry, Graduate School of Medicine, Kyoto University, 3. Institute of Applied Brain Sciences, Waseda University, 4. School of Human and Social Sciences, Tokyo International University, 5. Department of Psychology, University of Oregon, 6. Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University)

^○Akira IWANAMI¹, Kazuhiko SAITO², Masakazu FUJIWARA³, Daiki OKUTSU⁴, Hironobu ICHIKAWA⁵ (1. Department of Psychiary, Showa University, School of Medicine, 2. Aiiku Institute, AI-Iku counseling Office, 3. SHIONOGI & CO., LTD., 4. SHIONOGI & CO., LTD., 5. JDDnet)

^○Akira IWANAMI¹, Kazuhiko S², Masakazu F³, Daiki OKUTSU⁴, Hironobu ICHIKAWA⁵ (1. Department of Psychiary, Showa University, School of Medicine, 2. Aiiku Institute, AI-Iku counseling Office, 3. SHIONOGI & CO., LTD., 4. SHIONOGI & CO., LTD., 5. JDDnet)

^○Atsushi KITAMURA, Takeshi TAKAGAKI, Daisuke NEMOTO, Yoshiko TOMITA, Hironori NISHIBE, Hiroyoshi KAKUYAMA, Katsunori MARUTA (Clinical Research, Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd.)

^○Masayasu TANAKA, Takayuki MURAKAMI (Formulation Research & Development Lab. Sumitomo Dainippon Pharma Co.,Ltd. ,Osaka, Japan)